

Non-Alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug Type (Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc), By End-use, By Region, And Segment Forecasts, 2022 - 2030

<https://marketpublishers.com/r/NEA26FDB0BF4EN.html>

Date: August 2022

Pages: 110

Price: US\$ 5,950.00 (Single User License)

ID: NEA26FDB0BF4EN

Abstracts

This report can be delivered to the clients within 5 Business Days

Non-Alcoholic Steatohepatitis Treatment Market Growth & Trends

The global non-alcoholic steatohepatitis treatment market size is expected to reach USD 15.95 billion by 2030, according to a new report by Grand View Research, Inc. The industry is projected to expand at a CAGR of 39.2% from 2022 to 2030. The non-alcoholic steatohepatitis (NASH) treatment market is primarily driven by the launch of drugs such as Novo Nordisk's Ozempic, Intercept's Ocaliva, and Inventiva's lanifibranor, among others.

The NASH treatment market has major unmet needs owing to factors such as the unavailability of approved drugs, high disease burden, and complex diagnostic procedures. Currently, the market is dominated by off-label drugs such as Pioglitazone and Vitamin E. These are widely prescribed drugs in this space globally. However, to address the unmet opportunity, key market players are heavily investing in R&D activities to develop novel therapeutics for NASH treatment. Currently, there are more than 50 pipeline candidates.

Some of the late-stage pipeline candidates expected to launch during the forecast period include Inventiva Pharma's Lanifibranor, Intercept Pharmaceuticals' Obeticholic acid, Galmed Pharmaceuticals Ltd.'s Aramchol, Novo Nordisk A/S's Semaglutide, and

Madrigal Pharmaceuticals, Inc.'s Resmetirom. Among these, Intercept Pharmaceuticals's Obeticholic Acid (OCA), and Madrigal Pharmaceuticals, Inc.'s Resmetirom, are the most looked upon drugs and are expected to enter comparatively earlier than other pipeline candidates.

Research studies reveal that non-alcoholic steatohepatitis is strongly associated with obesity and diabetes. Research studies show that around 80% of NASH patients are obese. In countries such as the U.S., the obesity prevalence is as high as 42%, according to the latest 2021 statistics by CDC. In addition, countries such as the U.S. and Japan account for the highest prevalence of non-alcoholic steatohepatitis globally, and these countries also have a high burden of obesity and diabetes. All such factors will fuel the NASH treatment market throughout the forecast period.

Strategic initiatives by pharma giants and supportive regulatory authority policies such as fast track designation are further expected to accelerate the market growth. In May 2022, Pfizer, Inc.'s Ervogastat/Clesacostat Combination therapy received fast track designation. This is one of the potential drug combinations for the treatment of non-alcoholic steatohepatitis. Such drug designation boosts the clinical trial process for drugs.

Liver biopsy is the gold standard for the diagnosis of non-alcoholic steatohepatitis. The invasive nature of this diagnostics test limits its usage to only symptomatic cases, and as a result, the global average diagnostic rate for NASH is around 20%. The unavailability of biomarkers-based non-invasive tests for the diagnosis of non-alcoholic steatohepatitis is expected to impede the market growth.

Non-Alcoholic Steatohepatitis Treatment Market Report Highlights

Vitamin E and Pioglitazone (Off-label) acted as the lone contributor with 100% share to the market in 2021. This can be attributed to the unavailability of approved drugs in the market

The retail and specialty pharmacies segment held a share of 63.8% in 2021. Retail and specialty pharmacies are more compatible with chronic diseases such as NASH, where the patients are more commonly associated with homecare settings

North America dominated the overall NASH treatment space in terms of revenue. This can be attributed to increased disease awareness, better

healthcare facilities, and comparatively higher treatment rate than in other regions

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market Segmentation and Scope
 - 1.1.1 Segment scope
 - 1.1.2 Regional scope
 - 1.1.3 Estimates and forecast timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
 - 1.3.1 Purchased database
 - 1.3.2 GVR's internal database
 - 1.3.3 Secondary sources
 - 1.3.4 Primary research
 - 1.3.5 Details of primary research
- 1.4 Information or Data Analysis
 - 1.4.1 Data analysis models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
 - 1.6.1 Commodity Flow Analysis
 - 1.6.1.1 Approach: Commodity Flow Approach
- 1.7 Research Assumptions
- 1.8 List of Secondary Sources
- 1.9 List of Abbreviations
- 1.10 Objectives
 - 1.10.1 Objective
 - 1.10.2 Objective
 - 1.10.3 Objective
 - 1.10.4 Objective

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market Summary

CHAPTER 3 NON-ALCOHOLIC STEATOHEPATITIS TREATMENT MARKET VARIABLES, TRENDS, AND SCOPE

- 3.1 Penetration and Growth Prospect Mapping
- 3.2 Regulatory Landscape

- 3.3 Industry Analysis - Porter's Five Forces
- 3.4 PESTEL Analysis (Political & Legal, Economic, and Technological)
- 3.5 Epidemiology Analysis
- 3.6 Unmet need analysis
- 3.7 Pipeline Analysis, by Phase

CHAPTER 4 NON-ALCOHOLIC STEATOHEPATITIS TREATMENT MARKET: SEGMENT ANALYSIS, BY DRUG TYPE, 2018 - 2030 (USD MILLION)

- 4.1 Non-Alcoholic steatohepatitis treatment market: Drug Type Movement Analysis
- 4.2 Vitamin E and Pioglitazone
 - 4.2.1 Vitamin E and Pioglitazone Market, 2018 - 2030 (USD Million)
- 4.3 Obeticholic Acid (OCA)
 - 4.3.1 Obeticholic Acid (OCA) market, 2018 - 2030 (USD Million)
- 4.4 Lanifibranor
 - 4.4.1 Lanifibranor Market, 2018 - 2030 (USD Million)
- 4.5 Semaglutide
 - 4.5.1 Semaglutide Market, 2018 - 2030 (USD Million)
- 4.6 Resmetirom
 - 4.6.1 Resmetirom Market, 2018 - 2030 (USD Million)
- 4.7 Aramchol
 - 4.7.1 Aramchol Market, 2018 - 2030 (USD Million)
- 4.8 Cenicriviroc
 - 4.8.1 Cenicriviroc Market, 2018 - 2030 (USD Million)
- 4.9 Others
 - 4.9.1 Others Market, 2018 - 2030 (USD Million)

CHAPTER 5 NON-ALCOHOLIC STEATOHEPATITIS TREATMENT MARKET: SEGMENT ANALYSIS, BY END-USE, 2018 - 2030 (USD MILLION)

- 5.1 Non-Alcoholic steatohepatitis treatment market: End-use Movement Analysis
- 5.2 Hospital Pharmacies
 - 5.2.1 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
- 5.3 Retail and Specialty Pharmacies
 - 5.3.1 Retail and Specialty Pharmacies Market, 2018 - 2030 (USD Million)
- 5.4 Others
 - 5.4.1 Others Market, 2018 - 2030 (USD Million)

CHAPTER 6 NON-ALCOHOLIC STEATOHEPATITIS TREATMENT MARKET:

SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)

6.1 Definition & Scope

6.2 Regional Market Share Analysis, 2021 & 2030

6.3 Regional Market Snapshot

6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030

6.4.1 North America

6.4.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)

6.4.1.2 U.S.

6.4.1.2.1 U.S. Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.1.3 Canada

6.4.1.3.1 Canada Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.2 Europe

6.4.2.1 Europe Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.2.2 UK

6.4.2.2.1 UK Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.2.3 Germany

6.4.2.3.1 Germany Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.2.4 Spain

6.4.2.4.1 Spain Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.2.5 France

6.4.2.5.1 France Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.2.6 Italy

6.4.2.6.1 Italy Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.3 Asia Pacific

6.4.3.1 Asia Pacific Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.3.2 Japan

6.4.3.2.1 Japan Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.3.3 China

6.4.3.3.1 China Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.3.4 India

6.4.3.4.1 India Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.3.5 South Korea

6.4.3.5.1 South Korea Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.3.6 Australia

6.4.3.6.1 Australia Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.4 Latin America

6.4.4.1 Latin America Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.4.2 Brazil

6.4.4.2.1 Brazil Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.4.3 Mexico

6.4.4.3.1 Mexico Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.4.4 Argentina

6.4.4.4.1 Argentina Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.5 MEA

6.4.5.1 MEA Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.5.2 South Africa

6.4.5.2.1 South Africa Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.5.3 Saudi Arabia

6.4.5.3.1 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

6.4.5.4 UAE

6.4.5.4.1 UAE Non-Alcoholic steatohepatitis treatment market, 2018 - 2030 (USD Million)

CHAPTER 7 NON-ALCOHOLIC STEATOHEPATITIS TREATMENT MARKET: COMPETITIVE ANALYSIS

7.1 Recent Developments and Impact Analysis, by Key Market Participants

7.1.1 New Product Launches

7.1.2 Mergers and Acquisitions

7.1.3 Partnerships and Strategic Collaboration

7.2 Company Categorization

7.2.1 Innovators

7.2.2 Market Leaders

7.3 Vendor Landscape

7.3.1 List of key distributors and channel partners

7.4 Key Customers

7.5 Key Company Market Share Analysis, 2021

7.6 Public Companies

7.6.1 Company market position analysis

7.6.2 Competitive Dashboard Analysis

7.6.1.1 Market Differentiators

7.7 Private Companies

7.7.1 List of key emerging companies

7.7.2 Regional Network Map

7.8 Company Profiles

7.8.1 Intercept Pharmaceuticals

7.8.1.1 Company overview

7.8.1.2 Financial performance

7.8.1.3 Product benchmarking

7.8.1.4 Strategic initiatives

7.8.2 Galmed Pharmaceuticals

7.8.2.1 Company overview

7.8.2.2 Financial performance

7.8.2.3 Product benchmarking

7.8.3 Inventiva Pharma

7.8.3.1 Company overview

7.8.3.2 Financial performance

7.8.3.3 Product benchmarking

7.8.4 Novo Nordisk A/S

7.8.4.1 Company overview

7.8.4.2 Financial Performance

7.8.4.3 Product Benchmarking

7.8.4.4 Strategic initiatives

7.8.5 AbbVie Inc.

7.8.5.1 Company overview

- 7.8.5.3 Financial Performance
- 7.8.5.4 Product benchmarking
- 7.8.5.5 Strategic initiatives
- 7.8.6 Galectin Therapeutics Inc.
 - 7.8.6.1 Company overview
 - 7.8.6.2 Financial performance
 - 7.8.6.3 Product benchmarking
 - 7.8.6.4 Strategic initiatives
- 7.8.7 Madrigal Pharmaceuticals
 - 7.8.7.1 Company overview
 - 7.8.7.2 Product benchmarking
- 7.8.8 NGM Biopharmaceuticals Inc.
 - 7.8.8.1 Company overview
 - 7.8.8.2 Financial performance
 - 7.8.8.3 Product benchmarking
 - 7.8.8.4 Strategic initiatives
- 7.8.9 Bristol Myers Squibb
 - 7.8.9.1 Company overview
 - 7.8.9.2 Financial performance
 - 7.8.9.3 Product benchmarking
 - 7.8.9.4 Strategic initiatives
- 7.8.10 Novo Nordisk A/S
 - 7.8.10.1 Company overview
 - 7.8.10.2 Financial performance
 - 7.8.10.3 Product benchmarking
 - 7.8.10.4 Strategic initiatives
- 7.8.11 Gilead Sciences Inc
 - 7.8.11.1 Company overview
 - 7.8.11.2 Financial performance
 - 7.8.11.3 Product benchmarking
 - 7.8.11.4 Strategic initiatives?

List Of Tables

LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviation

Table 3 Incidence of Diseases

Table 4 Global Non-Alcoholic steatohepatitis treatment market, By Region, 2018 - 2030 (USD Million)

Table 5 Global Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 6 Global Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 7 North America Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)

Table 8 North America Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 9 North America Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 10 U.S. Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 11 U.S. Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 12 Canada Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 13 Canada Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 14 Europe Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)

Table 15 Europe Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 16 Europe Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 17 Germany Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 18 Germany Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 19 UK Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 20 UK Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 21 France Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 22 France Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 23 Italy Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 24 Italy Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 25 Spain Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 26 Spain Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 27 Asia Pacific Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)

Table 28 Asia Pacific Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 29 Asia Pacific Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 30 Japan Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 31 Japan Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 32 China Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 33 China Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 34 India Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 35 India Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 36 South Korea Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 37 South Korea Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 38 Australia Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 39 Australia Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 -

2030 (USD Million)

Table 40 Latin America Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)

Table 41 Latin America Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 42 Latin America Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 43 Brazil Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 44 Brazil Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 45 Mexico Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 46 Mexico Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 47 Argentina Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 48 Argentina Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 49 Middle East & Africa Non-Alcoholic steatohepatitis treatment market, By Country, 2018 - 2030 (USD Million)

Table 50 Middle East & Africa Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 51 Middle East & Africa Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 52 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 53 Saudi Arabia Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 54 South Africa Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 55 South Africa Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

Table 56 UAE Non-Alcoholic steatohepatitis treatment market, By Drug Type, 2018 - 2030 (USD Million)

Table 57 UAE Non-Alcoholic steatohepatitis treatment market, By End-Use, 2018 - 2030 (USD Million)

List Of Figures

LIST OF FIGURES

- FIG. 1 Non-Alcoholic steatohepatitis treatment market Segmentation
- FIG. 2 Market research process
- FIG. 3 Data triangulation techniques
- FIG. 4 Primary research pattern
- FIG. 5 Market research approaches
- FIG. 6 Value-chain-based sizing & forecasting
- FIG. 7 QFD modeling for market share assessment
- FIG. 8 Market formulation & validation
- FIG. 9 Non-alcoholic steatohepatitis treatment market snapshot
- FIG. 10 Parent market outlook
- FIG. 11 Related/ancillary market outlook, revenue, 2021 (USD Million)
- FIG. 12 Penetration and growth prospect mapping
- FIG. 13 Non-alcoholic steatohepatitis treatment market driver impact
- FIG. 14 Non-alcoholic steatohepatitis treatment market restraint impact
- FIG. 15 SWOT analysis, by factor (political & legal, economic, and technological)
- FIG. 16 Industry Analysis - Porter's Five Forces
- FIG. 17 Strategy mapping
- FIG. 18 Non- alcoholic steatohepatitis treatment market: Drug type outlook and key takeaways
- FIG. 19 Non- alcoholic steatohepatitis treatment market: Drug type movement analysis & market share 2021 & 2030
- FIG. 20 Vitamin E and Pioglitazone non-alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 21 Obeticholic Acid non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 22 Lanifibranor non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 23 Semaglutide non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 24 Resmetirom non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 25 Aramchol non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 26 Cenicriviroc non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 27 Others non - alcoholic steatohepatitis treatment market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 28 Non- alcoholic steatohepatitis treatment market: End-use outlook and key takeaways

FIG. 29 Non- alcoholic steatohepatitis treatment market: End-use movement analysis & market share 2021 & 2030

FIG. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 31 Retail and speciality pharmacies market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 33 Non-alcoholic steatohepatitis treatment market: Regional outlook and key takeaways

FIG. 34 Regional outlook, 2021 & 2030

FIG. 35 North America

FIG. 36 North America market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 37 U.S.

FIG. 38 U.S. market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 39 Canada

FIG. 40 Canada market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 41 Europe

FIG. 42 Europe market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 43 UK

FIG. 44 UK market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 45 Germany

FIG. 46 Germany market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 47 France

FIG. 48 France market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 49 Italy

FIG. 50 Italy market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 51 Spain

FIG. 52 Spain market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 53 Asia-Pacific

FIG. 54 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 55 Japan

FIG. 56 Japan market estimates and forecast, 2018 - 2030(USD Million)

FIG. 57 China

FIG. 58 China market estimates and forecast, 2018 - 2030 (USD Million)

FIG. 59 India

FIG. 60 India market estimates and forecast, 2018 - 2030 (USD Million)

- FIG. 61 South Korea
- FIG. 62 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 63 Australia
- FIG. 64 Australia market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 65 Latin America
- FIG. 66 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 67 Brazil
- FIG. 68 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 69 Mexico
- FIG. 70 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 71 Argentina
- FIG. 72 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 73 Middle East & Africa
- FIG. 74 MEA market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 75 South Africa
- FIG. 76 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 77 Saudi Arabia
- FIG. 78 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 79 UAE
- FIG. 80 UAE market estimates and forecast, 2018 - 2030 (USD Million)
- FIG. 81 Market differentiators
- FIG. 82 Key company market share analysis, 2021
- FIG. 83 Company market position analysis
- FIG. 84 Competitive dashboard analysis
- FIG. 85 Regional network map

I would like to order

Product name: Non-Alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug Type (Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc), By End-use, By Region, And Segment Forecasts, 2022 - 2030

Product link: <https://marketpublishers.com/r/NEA26FDB0BF4EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NEA26FDB0BF4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970